세계의 골수이형성증후군(MDS) 치료 시장 규모 : 치료 종류, 최종사용자, 지역별 예측(2022-2028년)

Global Myelodysplastic Syndrome (MDS) Treatment Market is valued at approximately USD XXXX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2022-2028. Myelodysplastic Syndrome (MDS) Treatment is a term used to describe a category of bone marrow disorders in which the bone marrow fails to create enough healthy blood cells. MDS is also known as "bone marrow failure condition". Ineffective hematopoiesis, as well as anomalies in proliferation, differentiation, and apoptosis, characterise these illnesses. The increased R&D spending on new drug development and increasing public awareness have led to the adoption of Myelodysplastic Syndrome (MDS) Treatment across the forecast period. For Instance: as per Cancer.Net in 2022, every year, about 10,000 people in the United States are diagnosed with MDS. MDS is rare in adults under the age of 50. People in their 70s are the most likely to develop it. The number of people diagnosed with MDS each year is projected to rise as the US population continues to age. As per Congressional Budget Office 2021, the pharmaceutical sector spent $83 billion on research and development in 2019. Inflation-adjusted, that sum is around ten times what the industry spent every year in the 1980s. Also, some initiatives by the government to provide targeted therapies and attractive reimbursement policies are likely to increase the market growth during the forecast period. However, adverse effects caused by the medicine may impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Myelodysplastic Syndrome (MDS) Treatment market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to increased R&D spending on new drug development and increasing public awareness. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2022-2028. Factors such as initiatives by the government to provide targeted therapies and attractive reimbursement policies would create lucrative growth prospects for the Myelodysplastic Syndrome (MDS) Treatment market across Asia-Pacific region.

Major market players included in this report are:

AbbVie Inc.

Accord Healthcare

Bristol-Myers Squibb

Jazz Pharmaceuticals Inc

Novartis AG

Lupin Pharmaceuticals

Otsuka America Pharmaceutical Inc.

Onconova Therapeutics

Takeda Pharmaceutical Company Limited

Astex Pharmaceuticals, Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment:

Chemotherapy,

Immune Treatments

Stem Cell Transplant

Other Treatment Types

By End-User:

Hospitals

Specialty Clinics

Other End-Users

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019, 2020

Base year - 2021

Forecast period - 2022 to 2028

Target Audience of the Global Myelodysplastic Syndrome (MDS) Treatment Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Billion)
  • 1.2.1. Myelodysplastic Syndrome (MDS) Treatment Market, by Region, 2020-2028 (USD Billion)
  • 1.2.2. Myelodysplastic Syndrome (MDS) Treatment Market, by Treatment Type, 2020-2028 (USD Billion)
  • 1.2.3. Myelodysplastic Syndrome (MDS) Treatment Market, by End-User, 2020-2028 (USD Billion)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Myelodysplastic Syndrome (MDS) Treatment Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Myelodysplastic Syndrome (MDS) Treatment Market Dynamics

• 3.1. Myelodysplastic Syndrome (MDS) Treatment Market Impact Analysis (2020-2028)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increased R&D spending on new drug development
    • 3.1.1.2. Increasing public awareness
  • 3.1.2. Market Challenges
    • 3.1.2.1. Adverse effects caused by the medicine
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Initiatives by the government to provide targeted therapies and attractive reimbursement policies

Chapter 4. Global Myelodysplastic Syndrome (MDS) Treatment Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
• 4.2. PEST Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
• 4.3. Investment Adoption Model
• 4.4. Analyst Recommendation & Conclusion
• 4.5. Top investment opportunity
• 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1.1. Assessment of the overall impact of COVID-19 on the industry
• 5.1.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Myelodysplastic Syndrome (MDS) Treatment Market, by Treatment Type

• 6.1. Market Snapshot
• 6.2. Global Myelodysplastic Syndrome (MDS) Treatment Market by Treatment Type, Performance - Potential Analysis
• 6.3. Global Myelodysplastic Syndrome (MDS) Treatment Market Estimates & Forecasts by Treatment Type, 2018-2028 (USD Billion)
• 6.4. Myelodysplastic Syndrome (MDS) Treatment Market, Sub Segment Analysis
  • 6.4.1. Chemotherapy
  • 6.4.2. Immune Treatments
  • 6.4.3. Stem Cell Transplant
  • 6.4.4. Other Treatment Types

Chapter 7. Global Myelodysplastic Syndrome (MDS) Treatment Market, by End-User

• 7.1. Market Snapshot
• 7.2. Global Myelodysplastic Syndrome (MDS) Treatment Market by End-User, Performance - Potential Analysis
• 7.3. Global Myelodysplastic Syndrome (MDS) Treatment Market Estimates & Forecasts by End-User, 2018-2028 (USD Billion)
• 7.4. Myelodysplastic Syndrome (MDS) Treatment Market, Sub Segment Analysis
  • 7.4.1. Hospitals
  • 7.4.2. Specialty Clinics
  • 7.4.3. Other End-Users

Chapter 8. Global Myelodysplastic Syndrome (MDS) Treatment Market, Regional Analysis

• 8.1. Myelodysplastic Syndrome (MDS) Treatment Market, Regional Market Snapshot
• 8.2. North America Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.2.1. U.S. Myelodysplastic Syndrome (MDS) Treatment Market
    • 8.2.1.1. Treatment Type breakdown estimates & forecasts, 2018-2028
    • 8.2.1.2. End-User breakdown estimates & forecasts, 2018-2028
  • 8.2.2. Canada Myelodysplastic Syndrome (MDS) Treatment Market
• 8.3. Europe Myelodysplastic Syndrome (MDS) Treatment Market Snapshot
  • 8.3.1. U.K. Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.3.2. Germany Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.3.3. France Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.3.4. Spain Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.3.5. Italy Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.3.6. Rest of Europe Myelodysplastic Syndrome (MDS) Treatment Market
• 8.4. Asia-Pacific Myelodysplastic Syndrome (MDS) Treatment Market Snapshot
  • 8.4.1. China Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.4.2. India Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.4.3. Japan Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.4.4. Australia Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.4.5. South Korea Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.4.6. Rest of Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market
• 8.5. Latin America Myelodysplastic Syndrome (MDS) Treatment Market Snapshot
  • 8.5.1. Brazil Myelodysplastic Syndrome (MDS) Treatment Market
  • 8.5.2. Mexico Myelodysplastic Syndrome (MDS) Treatment Market
• 8.6. Rest of The World Myelodysplastic Syndrome (MDS) Treatment Market

Chapter 9. Competitive Intelligence

• 9.1. Top Market Strategies
• 9.2. Company Profiles
  • 9.2.1. AbbVie Inc.
    • 9.2.1.1. Key Information
    • 9.2.1.2. Overview
    • 9.2.1.3. Financial (Subject to Data Availability)
    • 9.2.1.4. Product Summary
    • 9.2.1.5. Recent Developments
  • 9.2.2. Accord Healthcare
  • 9.2.3. Bristol-Myers Squibb
  • 9.2.4. Jazz Pharmaceuticals Inc
  • 9.2.5. Novartis AG
  • 9.2.6. Lupin Pharmaceuticals
  • 9.2.7. Otsuka America Pharmaceutical Inc.
  • 9.2.8. Onconova Therapeutics
  • 9.2.9. Takeda Pharmaceutical Company Limited
  • 9.2.10. Astex Pharmaceuticals, Inc.

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes
• 10.3. Research Assumption